Dr. Valdez is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1650 Selwyn Ave Fl 9
Bronx, NY 10457Phone+1 718-960-1020Fax+1 718-960-2033
Education & Training
Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Infectious Disease, 1994 - 1998
Henry Ford Health/Henry Ford HospitalResidency, Internal Medicine, 1991 - 1994
Cayetano Heredia UniversityClass of 1990
Certifications & Licensure
NY State Medical License 2004 - 2023
Clinical Trials
- The Effectiveness of GM-CSF in HIV-Positive Patients Who Are Also Receiving Anti-HIV Therapy
- Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315
- A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328
- Join now to see all
Publications & Presentations
PubMed
- 253 citationsHerpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid ArthritisKevin L. Winthrop, Hisashi Yamanaka, Hernan Valdez, Eric Mortensen, Robert Chew
Arthritis & Rheumatology. 2014-10-01 - 54 citationsRisk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid ArthritisChristina Charles-Schoeman, Ryan DeMasi, Hernan Valdez, Koshika Soma, Lie-Ju Hwang
Arthritis & Rheumatology. 2019-09-01 - 18 citationsEarly Quantification of Systemic Inflammatory Proteins Predicts Long-Term Treatment Response to Tofacitinib and EtanerceptLewis Tomalin, Jae Hwan Kim, Joel Correa da Rosa, Julie Lee, Lori Fitz
The Journal of Investigative Dermatology. 2020-05-01
Journal Articles
- Efficacy and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic DermatitisJonathan I Silverberg, Eric L Simpson, Hernan Valdez, JAMA Dermatology
Authored Content
- Modified- Versus Immediate-Release Tofacitinib in Japanese Rheumatoid Arthritis Patients: A Randomized, Phase III, Non-Inferiority StudyAugust 2018
Press Mentions
One More Phase 3 Trial Finds Abrocitinib Safe, Effective for Atopic DermatitisJune 13th, 2020- Efficacy and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic DermatitisJune 3rd, 2020
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
